Stock Market & Financial Investment News

News Breaks September 12, 2012 08:39 EDT CELG Celgene says beginning to see benefits of investments, strategic initiatives Comment made by CEO Bob Hugin at the Morgan Stanley Healthcare Conference. News For CELG From The Last 14 Days Check below for free stories on CELG the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 17, 2013 05:44 EDT CELG Celgene awarded marketing authorisation for Revlimid from EC Subscribe for More Information June 14, 2013 08:23 EDT CELG Celgene multiple likely to expand further, says Cantor Cantor believes that Celgene is in the process of diversifying its revenue as it introduces new products. The firm has an upbeat outlook on the company's Apremilast drug and keeps a Buy rating on the stock. 06:07 EDT CELG Celgene achieves statistical significance for endpoints in Behcet trial Subscribe for More Information June 13, 2013 10:15 EDT CELG Celgene management to meet with Jefferies Subscribe for More Information 10:14 EDT CELG Celgene management to meet with Guggenheim Subscribe for More Information 10:05 EDT CELG On The Fly: Analyst Upgrade Summary Subscribe for More Information 08:03 EDT CELG Celgene should continue to be bought, says RW Baird Baird continues to be buyers of Celgene citing its new $3B share repurchase program and the publication of new trial data for apremilast's PALACE-1 efficacy. Shares are Outperform rated with a $130 price target. 07:33 EDT CELG Celgene upgraded to Buy from Hold at Argus Subscribe for More Information 05:24 EDT CELG Celgene presents data from PALACE 3 study Celgene International Sŕrl, a wholly-owned subsidiary of Celgene, announced results from PALACE 3, the company’s third phase III study in psoriatic arthritis, or PsA, at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain. The PALACE 3 study, which evaluated 495 patients, demonstrated statistical significance in achieving the primary endpoint of American College of Rheumatology 20 score at week 16 for patients receiving apremilast compared to placebo. PALACE 3 is the third pivotal phase III, randomized, placebo-controlled study evaluating Celgene’s novel, oral small-molecule inhibitor of phophodiesterase 4 in patients with active psoriatic arthritis who had previously received and/or failed an oral disease-modifying anti-rheumatic drug, or DMARD, and/or biologic therapy. In this study, apremilast treatment was used alone or in combination with oral DMARDs. By design, PALACE 3 includes a subset of 270 patients with significant active psoriatic skin involvement. Patients in the 30 mg BID active treatment arm also demonstrated significant and sustained improvements in psoriasis-related endpoints, including Psoriasis Area Severity Index, or PASI, 50 and PASI-75 at week 24. Similar improvements in 30 mg BID-treated patients were also observed in key secondary endpoints, including various measures of physical function, signs and symptoms and quality of life. The safety and tolerability profile of apremilast in PALACE 3 was consistent with other previously reported phase III studies of the therapy in psoriatic arthritis. June 12, 2013 08:01 EDT CELG Celgene announces additional $3B share repurchase program Celgene announced that its Board of Directors authorized the repurchase of up to an additional $3.0B of the company’s common stock. Year-to-date, Celgene has repurchased approximately $1.8B of its common stock and has exhausted the previous $2.5B stock repurchase authorization. 08:00 EDT CELG Celgene announces additional $3B share repurchase program Subscribe for More Information 07:38 EDT CELG Celgene reports positive Phase III results from psoriatic arhrititis candidate Subscribe for More Information June 10, 2013 07:40 EDT CELG Leerink's biotech analyst holds analyst/industry conference call on ASCO Subscribe for More Information June 7, 2013 09:33 EDT CELG Celgene management to meet with Lazard Capital Meeting to be held in Zurich on June 14 hosted by Lazard Capital. June 6, 2013 06:19 EDT CELG Celgene implied volatility at upper end of index mean range June 5, 2013 13:02 EDT CELG FDA approves Celgene's supplemental new drug application for Revlimid Subscribe for More Information 07:48 EDT CELG FDA PDUFA Date for Celgene's Revlimid scheduled for June 5, 2013 Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.